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My discussion is about three committees 
on which I serve at the University of 
Michigan. Perhaps this will help to estab-
lish some principles with a few specific 
examples. The committee meetings must 
keep a certain confidentiality, which is 
easj}y solved he re by omitting individuals' 
and investigators' names. Also, I'll confine 
myself to classes of compound rather than 
specifie ones. 
Students as a group do not participate 
in all these committce actions, and this 
introduees eertain diffieulties. These stu-
dents, whom we are expected to te ach, 
have strong, diverse opinions. If we get one 
student on a eommittee, it may be good 
for his political standing with his fellows, 
but it doesn't teach the wh oIe class. I wish 
the whole class were involved in eommittee 
discussions, but then we would destroy 
the confidentiality. So, much of the teach-
ing aspect so important in these committee 
discussions is not available to the students. 
Regarding the first committee with 
which I have worked, the Radioisotope 
Committee, a prima!)' principle is that the 
pharmaeology of a eompound has a great 
deal to do with dccisions as to what is 
permissible in investigations. In 1947, this 
type of eommittee might bc considcred 
the grandfather of the peer review com-
mittees. By 1952, the Atomic Energy Co m-
mission had formal arrangements for regu-
lating the use of radioisotopes in human 
beings, and radiation poliey eommittees 
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were set up in the universities, with sub-
eommittees on human use. Our eommittee 
in Miehigan started in 1952. 
Table I shows a problem with an in-
vestigational drug using tritium. If 100 
microeuries of tritium is given in the form 
of water, the whole body dose is only 
about 8 millirads, which is about the dos-
age one gets from cosmic radiation in 
about one month in most parts of the 
United States. In general it isn't a very 
high dose. On the other hand, along came 
an applieation to use a eongener of cy-
tarabine because studies in animals didn't 
clcarly indicate how the human being 
would dispose of it. A company wanted to 
investigate this in human beings, using 100 
mierocurics of tritiated cytarabine con-
gener, which was not used in the pre-
vious 20 protocols. This posed prob-
lems. The drug is not like other tritiated 
compounds, for the genetic material 
would take it up. It is very diffieult to 
estimate how mueh this usc would incrcase 
the radiation dose to the genetie material. 
Estimates ranged from 15- to 1,000-fold 
increased biologie effeetiveness in this in-
stanee. We decided it just eould not be 
done exeept in people who could, for some 
reason, eventually benefit by it. This was 
an antiviral eompound and certain people 
with malignant diseases would be in serious 
trouble if they contracted a viral disease; 
this partieular compound might prove to 
be very helpful to them. Therefore, it 
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might be justifiable in those instances to 
ask them to participate as research sub-
jects. In fact, this study was not initiated 
at Michigan after an the discussions were 
complcted. 
Table II illustrates another principle, 
namely, that in certain circumstances you 
can proceed with an investigational tool 
on the basis that the subject has Httle to 
gain but nothing to lose. Consider first 
objections to use of 1311 in the form of 
radioiodinated serum albumin intrathecally. 
From the suggested 100 j-tC of this com-
pound ( 131 1-iodoalbumin), the whole body 
dose would be in the range of 30 to 150 
millirads with much higher local dose. 
If one wanted to give 50 millicuries of 
an 131I-chloroquine analogue the whole 
body dose would be almost 100 rads at the 
highest-a big whole body dose. Why was 
this permitted? Because the people in 
whom the investigators wished to use this 
analogue had disseminated malignant mel-
anoma, no other therapy was available and 
this was an attempt to treat them; in other 
words, it was intended for their own im-
mediate good. 
Now, there were questions as to whether 
it would help them, for melanoma is 
not a radiosensitive tumor (relatively) and, 
second, even in the usual black melanoma, 
not an cells are melanotic. Therefore, it 
was questionable whether these people 
would really get a cure from malignant 
mclanoma or get tremendous beneRt. On 
the other hand, it was considered unethical 
to refuse them this possibility. One could 
sit and watch them die or let this investiga-
tor try to do something for them. The 
choice was obvious. 
There are two ways to look at this: We 
have to consider the pharmacology of the 
compound and use clinical common sense 
as to what can be allowed and what can-
not. Thus, either we can find measures 
that are of such low risk that we don't 
have to think a great deal about whether 
the investigation is likely to help or not, 
or we find situations in wh ich the patient 
has so Httle to lose that it would be wrong 
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Table I. The case of the dangerous 
radioisotope 
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Prior to 1970, the Subcommittee on Human Use 
of Radioisotopes had approved 20 protocols using 
tritium in doses ranging from 2pc to 2mc. 
Application No. 21 requested the use of 100 pe 
to study the metabolic disposition of a congener 
of cytarabine 
Table II. The "hopeless" case 
The Subcommittee on Human Use of Radioiso-
topes restricted the use of 131I-iodoalbumin (in-
trathecal) to special diagnostic problems (e.g., 
CSF leaks), even though the established whole 
body dose from the administered 100pc ~ 30 to 
150 mracls. The spinal cord might receive a local 
dose as high as 40 to 60 rads 
Yet this Subcommittee approved administration of 
50 mc. of an experimental 131I-chloroquine an-
alogue systemically to certain patients. Their 
whole body dose is 70 to 95 rads 
to deny hirn this one chance in a thousand 
of being hclped. However, most of the 
time it isn't that simple and one has to 
make other decisions. We come now to the 
third principle, in situations involving the 
sccond review committee. 
By February 1966, the Surgeon Gen-
eral's edict, with which you are an familiar, 
had been issued, and by the end of March 
1966, we had a standing eommittee that 
dealt with various forms of human investi-
gation, quite apart from the Radioisotope 
Committee. 
Tablc In lists some examples of cases 
that plagued this review committee. A 
study that in itself was safe might frighten 
the subject. Tbe otologists were interested 
in obtaining audiograms to test the hearing 
of people who had terminal illnesses, in 
the event that some of them would come 
to autopsy. They might then be able to 
compare thc findings in the inner ear with 
the audiograms. Not everyone with a 
terminal illness is miserable and in pain at 
that time. The investigators were quite 
careful to stay away from anyone who was 
in pain or would in any way be harassed 
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Table III. Cases that plague review 
committees 
No. Gases 
1 Studies that are themselves safe and reason-
able but may still be frightening to the 
subject 
2 Studies that are themselves safe and reason-
able but may still be embarrassing to the 
subject 
3 Invasion of the body by indwelling eathe-
ters, ete. 
4 Studies during pregnaney and delivery 
5 Anesthesia 
by the procedure. The patient was, of 
course, not told he was being studied be-
cause of his condition. While the procedure 
had no benefit to hirn, the investigators 
wcre very careful to make sure it would 
not affect the patient's treatment, and, 
since an audiogram is a painless procedure, 
it is the kind of thing that could be allowed 
rather easily. However, by the "hospital 
grapevine," it would eventually become 
known that the audiograms were being 
used for this purpose and would frighten 
the persons concerned. Therefore, we just 
couldn't allow the investigators to select 
their subjects, no matter how careful they 
were with the terminally ill patients. 
Since it was a painless and harmless test 
and since the investigators were not doing 
this for anything except hearing research, 
we allowed them to do it provided thcy 
also sought out other people at random. 
Our concern was that they do nothing to 
frighten the subjects. 
We also had to deal with situations that 
involved embarrassment. For example, a 
psychiatrist wished to do something that 
required a follow-up of what had been 
done in the past. This meant following up 
people who had been seen in the student 
health center by a psychiatrist in previous 
years. The questionnaire they proposed 
was not unreasonable and the people were 
not in any way coerced to ans wer it. We 
had one problem, however. Many people 
are sent to psychiatrists in college for one 
thing or another. The psychiatrist may find 
Clinical Pharmacology 
and Therapeutics 
it to be a minor problem. Five years later, 
and after the person has left the college, 
suppose a letter arrives making reference 
to the fact that this person had been seen 
in psychiatry. Suppose his secretary 01' his 
wife opens the letter-it is like a voice out 
of the past! 
Although there was nothing in the letter 
that one would find offensive, it might be 
opened by someone other than the rightful 
recipient and cause embarrassment. There-
fore, we didn't think this should be al-
lowed, even though it was a very mild re-
quest-simply a letter asking for certain 
follow-up information from the subject 
himself. 
Number three in the list of problems be-
fore the review committee is much stickier. 
It involved investigation of hearing by a 
new method. It is very important to find 
out if a young child has normal hearing, to 
determine whether problems are associated 
with deafness 01' with mental retardation. 
Many children unfortunatcly are called 
mentally retarded even though they are 
very bright; the problem is with their poor 
hearing. In the younger age group, the 
proposed method of testing hearing was by 
evoked cochlear potential and involved put-
ting electrodes in the middle ear. The in-
vestigators wanted to start with adults. We 
feIt as folIows: No matter how much they 
told the person and no matter how un-
equivocally he consented, we wouldn't per-
mit puncturing the eardrum solely for 
research purposes, even if the subject 
understood exactly what was being done. 
Therefore, initially they had to start with 
people who already had punctured ear-
drums from previous disease 01' who had 
no eardrums. 
Now, wh at happens when you finally 
decide that this is a useful method and you 
wish to use this in an infant? Then it will 
require a myringotomy for the purpose of 
trying to help the infant. On the other 
hand, the first infant in whom this is done 
is still an experimental subject. How does 
one know the first time around that this 
investigation will actually help the child? 
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The switehing from adults to ehildren is 
very diffieult. Wh at are the rights of a par-
ent to eommit ehildren to investigation? 
Taking an example from obstetries, what 
are the rights of a parent to eommit a fetus 
to investigation? Do thcy have such rights? 
These are serious problems to deal with. 
Neverthelcss, we ean't stop a11 the prog-
ress in obstetries. In the long run, this 
would be to the dis advantage of pregnant 
women. Recently, some of us were prepared 
to veto a proposal to monitor the use of a 
prostagiandin as a method of inducing labor 
after the standard oxytocic hormone had 
failed. One investigator wanted a eatheter 
in the uterus through the abdominal wall. 
We said, "Ridiculous, we ean't allow a 
thing like that." It turned out that obstetri-
cians in many plaecs used that type of 
monitoring routincly in trying to induce 
labor. It can be part of medieal praetiee to 
put a catheter in thc uterus to monitor the 
progress of labor and their answer was, 
"Do you want to deprive a patient of an 
investigational drug-after the standard 
drug has failed-using the same protective 
monitoring that goes on with the standard 
drug?" Obviously, the answer then was 
"no." 
As to the fifth problem, we feel that gen-
eral anesthesia should not be indueed 
routinely purely for investigational pur-
poses. But what happens if you want to do 
early studies on a new anesthetic agent? 
Are you going to start with siek people? 
Are they to be the first to reecive a new 
general anesthetic? 
We had this problem in a prison study 
and we finally permitted short general 
anesthesia to be given for a few minutes 
as a Phase I study. It was administered by 
a professor of anesthesiology, with a pro-
fessor of pharnlaeology doing the monitor-
ing. Under these eonditions we would allow 
it, and no adverse effeets resulted. Never-
theless, we are always worried about gen-
eral anestheties. 
Subject seleetion requires eareful eon-
sideration. In my own experienee, I've 
found four types that eonstitute poor seIec-
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Table IV. The case of the poor selections 
Sub;ects who were poor candidates for 
No. drug studies 
1 A drug-seeking hippie 
2 A "yolunteer" under family pressure 
3 An attorney (!) 
4 A patient in danger oI sudden death 
tions (Tablc IV). People who are psychi-
atrically borderline are not good research 
subjects unless the study has to be done on 
psychiatrically borderline people. The first 
one listed was an individual who was 
regularly "on" all sorts of drugs on campus. 
He would make a vcry poor volunteer for a 
drug study, even though hc'd be delighted 
to take any drug that we would give him. 
Thc seeond was a so-ca11ed volunteer, 
but after I talked to him I discovered he 
was frightened and did not wish to par-
ticipate in research but was doing it under 
family coercion. Of course, we did not use 
him. 
Litigious persons are not good subjects. 
Maybe it's unfair to assume that attorneys 
involve themselves in lawsuits more than 
other people. 
Another pOOl' selection would be a pa-
tient in danger of sudden death, e.g., one 
who might have a sudden myoeardial in-
farct, even if the study had nothing in it 
that could precipitate a eardiac arrest. If 
you think thc volunteer is in such danger, 
he is a very poor subject to seleet. 
A very interesting case was presented to 
our committee by an investigator who 
wantcd to do endocrinc studies using stu-
dents as subjects. He wasn't studying con-
traception spccificaIly, but he wanted to 
leam thc effect of contraeeptive drugs on 
eertain endocrine functions. These girls were 
students, minors, unmarried, and they were 
told that they were going on eontraeeptives. 
But in thc original plan they would not 
have been specifieally told that the study 
would be contro11ed by placebo. This pro-
toeol received a fast veto (Table V). 
Aseries of studies has been conducted, 
beginning in 1964, in prison units similar 
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Table V. A case of poor planning 
An investigator proposed to the Committee 
to Study Clinical Research in Humans that 
he be allowed to conduct a study of oral 
No. contraceptives, using sub;ects who were: 
1 Unmarried 
2 Minors 
3 Students 
4 Also to be given placebo controls 
Table VI. The case of the successful 
protocol review committee 
The c1inical research activities at Southern Michi-
gan State Prison in the first 5 years of operation 
( 1964-1968) included 312 studies using 10,937 
subjects 
In the most re cent year (1970) 64 studies, using 
2,930 subjects, were conducted 
No instance of death or serious injury from a 
study has occurred since the beginning of the 
program 
in type to Deer Lodge in Montana. The 
units were established by Upjohn and Parke 
Davis at the Michigan State Prison in 
Jackson. Some statistics are given in Table 
VI. By using protocol review committees it 
has been possible to conduct a large num-
ber of studies and, as of 1970, there has not 
been a death or serious injury sinee the 
beginning of the program. 
These are mostly Phase I studies. One 
advantage of having a eommittee meet 
rather regularly is that with time it be-
eomes unnecessary to reject very many 
protoeols. The investigators soon leam wh at 
is and is not acceptable. After a while the 
acrimony tends to disappear, I believe, be-
cause certain things are known to be for-
bidden, and these are not proposed. This is 
the way it is done at Southem Michigan 
State Prison: Whcn an inmate is admitted 
to that prison he receives a notiee whieh he 
can send in if he wishes. Nobody ap-
proaches hirn directly to ask if he wishes 
to be part of the drug experirnentation 
group. Very few people volunteer initially. 
They wait until they have talked to other 
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Table VII. Cases of change in protocol 
From August 1969 through August 1971 the 
Michigan Protocol Review Committee modified 
submitted protocols for Phase I stt/dies as follows: 
Modifications I Instances 
Improved monitoring of subjects 34 
Exclusion of certain subjects 14 
Improved design and logistics of study 6 
Submission of additional preliminary 
data 3 
Improved informed consent 1 
Table VIII. Improved monitoring of 
sub;ects 
Improvements I Instances 
Amount of blood withdrawn 8 
Additional liver function studies 7 
Additional coagulation studies 5 
Change in dose schedule 4 
Electrocardiography 3 
Slit lamp examination 2 
Additional blood counts 2 
MisceIIaneous 3 
prisoners to find out wh ether they should 
participate. If they do volunteer they are 
interviewed by the people coneemed with 
the drug study. When the protocol is de-
veloped it has to be revicwcd by a protocol 
review committce consisting of physicians 
from the University of Michigan and others 
in private practiee in Jaekson, Michigan. 
There is also a physician from Wayne 
State University, and now an attomey has 
been added. A fcw statisties from the last 
two years' activities of that cornmittce are 
shown in Table VII. 
Thc most common objcetions we have 
made rder to monitoring. In several in-
stances we have insisted on closer monitor-
ing. In Phase I studies, the most important 
thing is to watch the subjects carefully for 
signs of adverse effect from the drug, signs 
of disturbed function of any kind. Then one 
must stop the medication. There is no way 
to raise the dose by increments in a Phase 
I study without very careful monitoring of 
the subjects. 
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Table IX. Exclusion 01 sub;ects 
Exclusion 
Prcvious rcaction 
Previous psychosis 
Previous phlebitis 
Previous exposure 
Previous Iivcr disease 
Multiple allergies 
Recent trauma 
Reccnt blood donor 
Eye disease 
Normal VDRL 
Cardiac abnormality 
Abnormal ECG 
Infection 
Gynecomastia 
Reason 
Vaccine to be used in the 
study 
Steroid to be used in the 
study 
Steroid to be used in the 
study 
ChloramphenicoI to be 
used in the study 
Creatinine phosphokinasc 
dcterminations important 
High risk of sensitization 
Heparin to be used 
Many blood sampIes 
needcd 
Long-term antilipid drug 
to be used 
Requires LP 
Antimalarial to be used 
CO exposure 
Sulfonamide to be used 
Steroid to be used 
Table VIII shows 34 protocols in which 
the monitoring was modiBed. The biggest 
problem was that the investigators might 
take too much blood. In a pharmacokinetic 
study, blood is taken serially and if one 
adds up the total amount, one may end 
by taking more blood than one would 
from a blood donor. This problem is now 
controlled by careful limitation of the 
amount of blood withdrawn. These peoplc 
are also givcn iron supplementation where 
indicatcd (Table VIII). 
Another aspect of a study is the exc1u-
sion of certain subjects. In one study the 
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invcstigators wanted to obtain spinal fluid. 
It was nccessary to explain what a spinal 
tap was; nevcrtheless, we were reluctant to 
approve it, as it reprcsented invasion of 
the body. On the other hand, in a prison 
thcre may be many peoplc who need lum-
bal' punetures because of a positive sero-
logie test for syphilis. Therefore these peo-
pIe could be available and they would 
themselves beneBt from the procedure 
(Table IX). 
Summary 
In summary, this was an attempt to set 
down some principles based on the work 
of three committees on which I have served. 
By means of some practical examples I 
have tried to suggest a few guidelines for 
conducting research with volunteers. I be-
lieve that such principles, illustrated by 
practical examples, are useful to investiga-
tors and aid in the guidance of committees 
in their function as review bodies. 
Any set of guidelines should be just that; 
if they are too rigid they are likely to lead 
to serious difficulty. If rigid guidelines are 
put into law and interpreted not only by 
various federal agencies at the top level but 
by middle bureauerats and lower echelon 
bureaucrats, bad mistakcs are likely. A 
truism in this work is the need for indi-
vidualizing each case to avoid the risk of 
mistakes arising from strict and inflexible 
application of the guidelincs. It is my hope 
that we can keep guidclines as aids for peer 
review groups in making individual deci-
sions, rather than as rigid rules. 
